By Conjoint Professor David goldstein

Journal articles

Chiang S; Garcia Netto K; Kokkinos J; Haghighi KS; Raina AS; Youkhana J; Pitiyarachchi O; Truong Q; Wenholz D; Wilkinson J; Laczka O; Li X; Aldilla VR; Kumar N; Goldstein D; Sharbeen G; Phillips PA, 2025, 'CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts', Scientific Reports, 15, http://dx.doi.org/10.1038/s41598-025-09411-2

Moharrami M; Watson E; Huang SH; Madathil S; Kim J; McPartlin A; Malik NH; Singhal S; Tsai CJ; Waldron J; Bratman S; Hope A; de Almeida J; Yao CM; Goldstein D; Quinonez C; Glogauer M; Hosni A, 2025, 'Defining the optimal radiation thresholds for Stratifying jaw osteoradionecrosis risk in head and neck cancer', Radiotherapy and Oncology, 209, http://dx.doi.org/10.1016/j.radonc.2025.110996

Soon YY; Sjoquist K; Marschner IC; Schou IM; Pavlakis N; Goldstein D; Shitara K; Stockler MR; Simes J; Martin AJ, 2025, 'INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.', JNCI Cancer Spectr, 9, http://dx.doi.org/10.1093/jncics/pkaf053

Michael M; Wong R; Gill S; Strickland AH; Pavlakis N; Shapiro JD; Link E; Farrell M; Ngan SY; Tie J; Heriot AG; Goldstein D; Mitchell C; Roth S; Wilson K; Mui M; Ramsay RG; Segelov E, 2025, 'The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-25-0705

Sousa MS; Garcia MV; Blanchard M; Daveson B; Currow D; Khan NN; Goldstein D; Findlay M; Landers A; Agar MR, 2025, 'Navigating pain and appetite challenges in palliative care for pancreatic cancer: insights from a national, longitudinal consecutive cohort study', Supportive Care in Cancer, 33, http://dx.doi.org/10.1007/s00520-025-09402-z

Ephraums J; Youkhana J; Raina AS; Schulstad G; Croft K; Mawson A; Kokkinos J; Gonzales-Aloy E; Ignacio RMC; McCarroll JA; Boyer C; Goldstein D; Pajic M; Haghighi KS; Johns A; Gill AJ; Erkan M; Initiative (APGI) APCG; Phillips PA; Sharbeen G, 2025, 'MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability', Neoplasia United States, 61, http://dx.doi.org/10.1016/j.neo.2025.101138

Biesma NC; Graus MUJE; Cirkel GA; Besselink MG; de Groot JWB; Koerkamp BG; Herbschleb KH; Los M; Verdonk RC; Wilmink JW; Cervantes A; Valle JW; Valkenburg-van Iersel LBJ; Froeling FEM; Molenaar IQ; Daamen LA; de Vos-Geelen J; van Santvoort HC; Bockorny B; Carrato A; Chen L; Coveler AL; Dajani O; Diaz LA; El-Rayes BF; Goldstein D; Halfdanarson TR; Hosein PJ; Kim EJ; Liang T; Melisi D; Pruijt JFM; Santoro A; Verschoor AJ; van Voorthuizen T, 2025, 'Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study', European Journal of Surgical Oncology, 51, http://dx.doi.org/10.1016/j.ejso.2024.109544

Bonazzi VF; Aoude LG; Brosda S; Bradford JJ; Lonie JM; Loffler KA; Gartside MG; Patel K; Mukhopadhyay P; Keane C; Gebski V; Kench JG; Goldstein D; Waddell N; Barbour AP, 2025, 'C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients', Asia Pacific Journal of Clinical Oncology, 21, pp. 77 - 86, http://dx.doi.org/10.1111/ajco.13993

Pavlakis N; Shitara K; Sjoquist K; Martin A; Jaworski A; Tebbutt N; Bang YJ; Alcindor T; O'Callaghan C; Strickland A; Rha SY; Lee KW; Kim JS; Bai LY; Hara H; Oh DY; Yip S; Zalcberg J; Price T; Simes J; Goldstein D, 2025, 'INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer', Journal of Clinical Oncology, 43, pp. 453 - 463, http://dx.doi.org/10.1200/JCO.24.00055

Manojlovic-Kolarski M; Su S; Weinreb I; Calvisi R; Perez-Ordonez B; Smith S; Patel S; Valero C; Xu B; Ghossein R; Katabi N; Clark J; Low TH; Gupta R; Graboyes E; Davies J; Richardson M; Goldstein D; Huang SH; O'sullivan B; Xu W; Hansen A; De Almeida JR, 2025, 'Adjuvant Chemoradiotherapy for Oral Cavity SCC With Minor and Major Extranodal Extension', JAMA Otolaryngology Head and Neck Surgery, http://dx.doi.org/10.1001/jamaoto.2025.1721

Trinh T; Au K; Krishnan AV; Timmins HC; Li T; Grimison P; Goldstein D; Park SB, 2025, 'Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuropathy: a cross-sectional cohort study', Acta Oncologica, 64, pp. 527 - 533, http://dx.doi.org/10.2340/1651-226X.2025.42935

Heinrich MC; Blay JY; Gelderblom H; George S; Schöffski P; Von Mehren M; Zalcberg JR; Jones RL; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Boye K; Goldstein D; Sánchez C; Siontis BL; Cox P; Davis E; Sherman ML; Ruiz-Soto R; Bauer S, 2025, 'Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE', Journal of Clinical Oncology, http://dx.doi.org/10.1200/JCO-24-02818

Li T; Goldstein D; Park SB, 2025, 'What you measure matters: The importance of outcome measures in evaluating the prevalence of painful chemotherapy-induced peripheral neuropathy', Regional Anesthesia and Pain Medicine, http://dx.doi.org/10.1136/rapm-2025-106586

Naher SK; Espinoza D; Grimison PS; Shitara K; Pavlakis N; Goldstein D; Stockler MR; Mercieca-Bebber R; Sjoquist K, 2025, 'Development and validation of a prognostic model for advanced gastric and oesophageal carcinoma (AGOC) using individual patient data from two clinical trials.', Journal of Clinical Oncology, 43, pp. 499 - 499, http://dx.doi.org/10.1200/jco.2025.43.4_suppl.499

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Tzelnick S; de Almeida JR; Yao CMKL; Kibel S; Kuehne N; Grewal R; Butler MO; Saibil S; Spreafico A; Easson A; Goldstein DP, 2024, 'Nodal Metastases in Stage 3 Head and Neck Melanoma: Patterns of Metastases and Patterns of Failure', Laryngoscope, 134, pp. 4292 - 4297, http://dx.doi.org/10.1002/lary.31515

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy', JAMA Network Open, 7, pp. e2424139, http://dx.doi.org/10.1001/jamanetworkopen.2024.24139

Niederberger M; Schifano J; Deckert S; Hirt J; Homberg A; Köberich S; Kuhn R; Rommel A; Sonnberger M; Alam M; Backman C; Banno M; Bartoszko J; Bloomfield F; Bober MB; Chalkoo M; Chan TM; Chen Y; Coscia C; de Luca K; Demartines N; Farzandipour M; Goldstein D; Goodman C; Grant S; Hübner M; Harris T; Howell M; Huber AM; Jansen TL; Johnson N; Julious SA; Kenny GP; Konge L; Kopkow C; LaPrade RF; Lim M; Loudovici-Krug D; Ma Y; MacLennan S; Mokkink LB; Montero M; Myles PS; Nayahangan LJ; Pace NL; Page MJ; Parente F; Payne K; Petrovic M; Sprung CL; Raveendran K; Roller-Wirnsberger R; Sconfienza LM; Spinelli A; van der Heijde D; Vohra S; Weissman JS; Westby M; Wu Y; Yadlapati R; Yarris LM; Zhang X, 2024, 'Delphi studies in social and health sciences—Recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a Delphi study', Plos One, 19, http://dx.doi.org/10.1371/journal.pone.0304651

Duguet-Armand M; Su J; OSullivan B; de Almeida J; Hosni A; Weinreb I; Perez-Ordonez B; Smith S; Witterick I; Yao C; Goldstein D; Hope A; Hahn E; Waldron J; Ringash J; Spreafico A; Yu E; Huang SH, 2024, 'Radiology-Pathology Concordance and Prognostication of Nodal Features in pN plus Oral Cavity Cancer', LARYNGOSCOPE, http://dx.doi.org/10.1002/lary.31578

De Almeida JR; Martino R; Hosni A; Goldstein DP; Bratman SV; Chepeha DB; Waldron JN; Weinreb I; Perez-Ordonez B; Yu E; Metser U; Hansen AR; Xu W; Su SJ; Kim J, 2024, 'Transoral Robotic Surgery and Radiation Volume Deintensification in Unknown Primary Squamous Cell Carcinoma of the Neck: The Phase 2 FIND Nonrandomized Controlled Trial', JAMA Otolaryngology Head and Neck Surgery, 150, pp. 463 - 471, http://dx.doi.org/10.1001/jamaoto.2024.0423

Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016

Li T; Trinh T; Bosco A; Kiernan MC; Goldstein D; Park SB, 2024, 'Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-024-08484-5

Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690

Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB, 2024, 'Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity', Jnccn Journal of the National Comprehensive Cancer Network, 22, pp. 108 - 116, http://dx.doi.org/10.6004/jnccn.2023.7083

Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB, 2024, 'Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity', Journal of the Neurological Sciences, 457, http://dx.doi.org/10.1016/j.jns.2023.122862

Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S, 2024, 'Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial', Nature Medicine, 30, pp. 498 - 506, http://dx.doi.org/10.1038/s41591-023-02734-5

Mahfouz FM; Li T; Joda M; Harrison M; Horvath LG; Grimison P; King T; Marx G; Goldstein D; Park SB, 2024, 'Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-023-08245-w

Zhang BYH; Georgiou C; Turner C; Kee D; Goldstein D; Haurat J; Bourne A; Turner M; Scott CL, 2024, '39O Four years and 1400+ patient referrals: Achievements of the Australian Rare Cancer Portal', ESMO Open, 9, pp. 102428 - 102428, http://dx.doi.org/10.1016/j.esmoop.2024.102428

Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL, 2024, 'Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck', CELL DEATH AND DIFFERENTIATION, 31, pp. 460 - 468, http://dx.doi.org/10.1038/s41418-024-01272-y

Lam LL; Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Yip S; Kang YK; Bang YJ; Chen LT; Moehler M; Bekaii-Saab T; Alcindor T; O’Callaghan CJ; Tebbutt NC; Hague W; Chan H; Rha SY; Lee KW; Gebski V; Jaworski A; Zalcberg J; Price T; Simes J; Goldstein D, 2023, 'INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)', BMC Cancer, 23, http://dx.doi.org/10.1186/s12885-023-10642-7

Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W, 2023, 'Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group', Journal of Clinical Oncology, 41, pp. 4714 - 4720, http://dx.doi.org/10.1200/JCO.22.02770

Gelderblom H; Jones RL; Blay JY; George S; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Harrow B; Becker C; Reichmann W; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S, 2023, 'Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study', European Journal of Cancer, 192, http://dx.doi.org/10.1016/j.ejca.2023.113245

Abdelmogod A; Papadopoulos L; Riordan S; Wong M; Weltman M; Lim R; McEvoy C; Fellowes A; Fox S; Bedő J; Penington J; Pham K; Hofmann O; Vissers JHA; Grimmond S; Ratnayake G; Christie M; Mitchell C; Murray WK; McClymont K; Luk P; Papenfuss AT; Kee D; Scott CL; Goldstein D; Barker HE, 2023, 'A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review', Cancers, 15, http://dx.doi.org/10.3390/cancers15174378

Mekapogu AR; Xu Z; Pothula S; Perera C; Pang T; Hosen SMZ; Damalanka V; Janetka J; Goldstein D; Pirola R; Wilson J; Apte M, 2023, 'HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis', Cancer Letters, 568, http://dx.doi.org/10.1016/j.canlet.2023.216286

Clifford BK; Kaakoush NO; Tedla N; Goldstein D; Simar D, 2023, 'The effect of exercise intensity on the inflammatory profile of cancer survivors: A randomised crossover study', European Journal of Clinical Investigation, 53, pp. e13984, http://dx.doi.org/10.1111/eci.13984

Sjoquist KM; Martin A; Pavlakis N; Goldstein D; Tsobanis E; Moses D; Maher R; Hague W; Gebski V; Stockler MR; Simes RJ, 2023, 'Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4959 - 4965, http://dx.doi.org/10.1007/s00432-022-04404-4

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031

White D; Abdulla M; Park SB; Goldstein D; Moalem-Taylor G; Lees JG, 2023, 'Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy', Journal of the Peripheral Nervous System, 28, pp. 179 - 190, http://dx.doi.org/10.1111/jns.12544

Michael M; Wong R; Gill SS; Strickland AH; Pavlakis N; Shapiro JD; Link E; Farrell M; Ngan SY; Heriot AG; Goldstein D; Mitchell C; Wilson K; Mui M; Ramsay RG; Segelov E, 2023, 'The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.', Journal of Clinical Oncology, 41, pp. 3616 - 3616, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3616

Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M; Epstein R; Vasey P; Shapiro J; Burge M; Chua YJ; Harris M; Pavlakis N; Tebbutt N; Prager G; Dittrich C; Längle F; Philipp-Abbrederis K; Greil R; Stöger H; Girschikofsky M; Kuehr T; Van Laethem JL; Laurent S; Dhani N; Ko YJ; Dowden S; Kavan P; Tehfe MÉ; Kubala E; Kohoutek M; Pfeiffer P; Yilmaz M; Parner V; Salminen T; Soveri LM; Korkeila E; Osterlund P; Taieb J; Tougeron D; Artru P; Caroli-Bosc FX; Guimbaud R; Turpin A; Walter T; Bachet JB; Kunzmann V; Kreth F; Block A; Venerito M; Oettle H; Karthaus M; Trojan J; Folprecht G; Lerch M; Kullmann F; Reiser M; Heinemann V; Wörns MA; Schulz H; Garlipp B; Yau T; Chan LS; Juhasz B; Landherr L; Pinter T; Bodoky G; Kahán Z; McDermott R; Power D; Gianni L; Siena S; Milella M; Falcone A; Berardi R, 2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134

Bekaii-Saab T; Okusaka T; Goldstein D; Oh DY; Ueno M; Ioka T; Fang W; Anderson EC; Noel MS; Reni M; Choi HJ; Goldberg JS; Oh SC; Li CP; Tabernero J; Li J; Foos E; Oh C; Van Cutsem E, 2023, 'Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial', Eclinicalmedicine, 58, http://dx.doi.org/10.1016/j.eclinm.2023.101897

Symons R; Daly D; Gandy R; Goldstein D; Aghmesheh M, 2023, 'Progress in the Treatment of Small Intestine Cancer', Current Treatment Options in Oncology, 24, pp. 241 - 261, http://dx.doi.org/10.1007/s11864-023-01058-3

Clifford BK; Amorim N; Kaakoush N; Boysen L; Tedla N; Goldstein D; Hardeman E; Simar D, 2023, 'Irradiation-Induced Dysbiosis: The Compounding Effect ofHigh-Fat Diet on Metabolic and Immune Functions in Mice', International Journal of Molecular Sciences, 24, pp. 5631 - 5631, http://dx.doi.org/10.3390/ijms24065631

Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Jaworski A; Yip S; Bang Y-J; Alcindor T; O'Callaghan CJ; Tebbutt NC; Strickland A; Rha SY; Lee K-W; Zalcberg JR; Price TJ; Simes J; Goldstein D, 2023, 'INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)-A study led by the Australasian Gastro-intestinal Trials Group (AGITG).', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. LBA294 - LBA294

Timmins HC; Mizrahi D; Li T; Kiernan MC; Goldstein D; Park SB, 2023, 'Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review', Journal of Cancer Survivorship, 17, pp. 222 - 236, http://dx.doi.org/10.1007/s11764-021-00988-x

Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB, 2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', Jnccn Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834

Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D, 2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for Immunotherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136

Back to profile page